Canada - English - Health Canada

novopharm limited - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

ivax pharmaceuticals incorporated - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

sandoz canada incorporated - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Malta - English - Medicines Authority

claris lifesciences uk limited - dobutamine - concentrate for solution for infusion - dobutamine 12.5 milligram(s)/millilitre - cardiac therapy

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride in 5% dextrose injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Israel - English - Ministry of Health

megapharm ltd - flecainide acetate - solution for injection - flecainide acetate 10 mg/ml - flecainide - flecainide - serious sustained life threatening ventricular arrhthymias that have not respoded to other drugs.

Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - solution for infusion - 5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - solution for infusion - 5 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine - solution for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to 12.5 mg/ml dobutamine excipient: sodium metabisulfite water for injection